LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Results from the phase 1/2 BRUIN study Meeting Abstract
| Authors: | Mato, A. R.; Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Lech-Marańda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; Roeker, L. E.; Patel, M. R.; Fakhri, B.; Barve, M.; Tam, C. S.; Lewis, D. J.; Gerson, J. N.; Alencar, A. J.; Taylor, J.; Abdel-Wahab, O.; Ghia, P.; Schuster, S. J.; Chen, J.; Nair, B.; Tsai, D.; Ku, N. C.; Davids, M. S.; Brown, J. R.; Jurczak, W. |
| Abstract Title: | LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Results from the phase 1/2 BRUIN study |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607547201176 |
| DOI: | 10.1182/blood-2020-134970 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 35 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
